HomeAI · summaries
Storia in 2 fonti
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
- ·
morningstar.com
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
- ·
Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC
HARMONi-6 showed 34% drop in death risk, but trial had an all-Asian population, expert warned
- ·
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and…
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
- ·
More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer
ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit